SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile shares are facing significant volatility following an 'off-nominal' orbital insertion of its BlueBird 7 satellite by Blue Origin's New Glenn rocket. While the community is actively debating the potential for an orbital recovery versus a total loss, the long-term investment thesis remains anchored by the company's insurance coverage and its continued production roadmap for subsequent satellites.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is experiencing significant market attention as a strategic partner to NVIDIA for quantum calibration and decoding, fueling a broader community narrative that the stock is currently mispriced compared to its peers. Investors are actively discussing the high-beta nature of the stock, analyzing the potential impacts of share unlock provisions, and debating its long-term potential as a key player in the quantum sensing and defense sectors.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is experiencing a surge in market activity driven by the U.S. government's executive order to fast-track research and regulatory review of psychedelic-based therapies. The stock is a primary focus for community members who are actively debating its potential for National Priority Vouchers, upcoming phase 3 trial results, and broader institutional re-rating as the psychedelic biotech sector gains significant policy tailwinds.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is drawing significant investor attention as analysts upgrade price targets, citing accelerating AI infrastructure demand and potential long-term benefits from custom silicon and optical networking partnerships. The community remains actively focused on Marvell's role in scaling hyperscale AI capacity, with many retail bulls highlighting the company's technical breakout as a signal of sustained momentum.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors debate the potential Phase 3 data for its lead oncology asset, GPS, while closely watching the upcoming AACR conference for disclosures on SLS009. The community remains deeply divided, with bulls highlighting successful clinical milestones and a potential buyout opportunity, while bears voice significant concerns regarding trial design, dosing modifications, and long-term financial viability.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is currently drawing significant attention from investors who view the stock as a compelling turnaround play following years of underperformance, with recent price action testing critical resistance levels. The community is actively debating the stock's stability, weighing a strong dividend yield and operational restructuring efforts against concerns over persistent shipping volume declines and rising fuel costs.

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies is drawing intense community attention due to a recent definitive agreement with crypto.com/us, which positions the company as a key player in the U.S. prediction markets sector. While investors debate the company's potential as a long-term unicorn and a candidate for a short squeeze, community sentiment remains sharply divided between those calling for triple-digit valuations and others warning of volatility common in low-float, high-volume trading.

The centrifuge token model powers centrifuge, providing the framework needed to run the platform without reliance on a single point of failure, including the centrifuge team or Company, and to accelerate its utility. To accomplish this, centrifuge leverages the cryptoeconomic primitives of a native token called the centrifuge token (cfg), a nominated-proof-of-stake consensus algorithm that employs centrifuge to stake value, rewards for centrifuge adoption, and an on-chain governance mechanism that empowers centrifuge holders to guide the development of centrifuge.

Centrifuge

Centrifuge is trending following the launch of the world's first licensed S&P 500 Index Fund Token, which the community views as a monumental advancement for institutional adoption and real-world asset tokenization. Investors are actively discussing the project's strategic partnerships and potential for bridging traditional finance with DeFi ecosystems, with many highlighting its infrastructure role in the sector.

Vanguard World Fund - Vanguard Information Technology ETF

Vanguard Information Technology ETF

Vanguard Information Technology ETF is seeing a surge in community interest as investors discuss its long-term growth potential and strong historical returns. Many are actively debating whether to accumulate shares during market volatility or wait for further pullbacks while highlighting the fund's efficiency and diversification compared to individual tech stocks.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing high volatility and intense community speculation driven by a presidential executive order aimed at fast-tracking research into ibogaine for mental health treatment. Investors are closely monitoring the stock's low float and institutional interest, leading to heated debates between bulls anticipating a short squeeze and skeptics warning of a potential sell-the-news event.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokerages

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has been given a consensus rating of "Buy" by the thirteen brokerages that are currently covering the firm, MarketBeat.com reports. One...

Wall Street Zen Upgrades Spyre Therapeutics (NASDAQ:SYRE) to "Hold"

Wall Street Zen upgraded shares of Spyre Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $95.00 at JonesTrading

JonesTrading increased their target price on shares of Spyre Therapeutics from $64.00 to $95.00 and gave the company a "buy" rating in a research report on Friday...

Top Biotech Stocks To Watch Today - April 16th

Danaher, Vertex Pharmaceuticals, argenex, Moderna, United Therapeutics, Capstone Therapeutics, and Spyre Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that develop, manufacture, or comm...

Spyre Therapeutics (NASDAQ:SYRE) Sees Large Volume Increase on Analyst Upgrade

Spyre Therapeutics (NASDAQ:SYRE) Sees Strong Trading Volume After Analyst Upgrade...

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up After Analyst Upgrade

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up Following Analyst Upgrade...

Robert W. Baird Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price

Robert W. Baird increased their price objective on shares of Spyre Therapeutics from $65.00 to $90.00 and gave the company an "outperform" rating in a research report on Tuesday...

<ul class="summary-bullets"><li>Spyre is looking forward to developing the drug as a single treatment, as well as in combination with its investigational antibodies SPY002 or SPY003.</li><li>TD Cowen says Spyre Therapeutics' data "strengthened our confidence in an already great dataset" for SPY001.</li><li>Leerink continues to view the trial data as a best-case outcome for SPY00, one which derisks both its potential as a monotherapy and backbone in future combination regimens.</li></ul>Shares of Spyre Therapeutics Inc. (SYRE) closed up 23% on Monday after several analysts upped their price targets on the stock on the heels of positive ulcerative colitis trial data, with several noting the company’s experimental drug’s potential against Takeda’s Entyvio.The stock marked its highest single-day gain on Monday since June 2023.Earlier in the day, Spyre announced positive data from part A of its phase 2 trial of SPY001 in the treatment of moderate-to-severely active ulcerative colitis. The company said that the trial met its primary endpoint of statistically significant reduction in disease activity.The drug was further well tolerated though six subjects experienced treatment-emergent adverse events, including a serious event which the company deems as not related to the drug.Spyre is looking forward to developing the drug as a single treatment as well as in combination with its investigational antibodies SPY002 or SPY003.<h2 class="st-heading-2">Analyst Take Away</h2>TD Cowen said Spyre Therapeutics' data "strengthened our confidence in an already great dataset" for SPY001. The firm has a ‘Buy’ rating on Spyre.Wedbush analyst David Nierengarten, meanwhile, raised the firm's price target on Spyre to $80 from $65 and kept an ‘Outperform’ rating on the shares. Spyre's SPY001 monotherapy surpassed historical benchmarks for Takeda's (TAK) Entyvio with 40% clinical remission and 51% endoscopic improvement, yielding an anticipated upside scenario, the analyst told investors in a research note.Leerink, which also has an ‘Outperform’ rating on the stock, raised the firm's price target on Spyre Therapeutics to $106 from $49. Leerink continues to view the trial data as a best-case outcome for SPY001, one which derisks both its potential as a monotherapy and backbone in future combination regimens. The target change reflects the firm's increased conviction and higher probability of success for SPY001 opportunities in UC and Crohn's disease, it said.Overall, the firm believes these "striking initial” study results represent best case data for SPY001, suggesting positively differentiated efficacy vs. Entyvio across a broad range of objective and symptomatic measures. The data position SPY001 as a leading agent in this multi-billion-dollar class, argues Leerink.Stoked by the data, BTIG analyst Julian Harrison also raised the firm's price target on Spyre to $98 from $70, and kept a ‘Buy’ rating on the shares while raising the firm's view of the odds of success for SPY001 combos in UC to 80% following the results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SYRE stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/SYRE">SYRE stock</a> has gained nearly 400% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/eras-stock-slumps-against-rvmd-rally-analyst-stays-bullish/cZJ8IHGRIuH">ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

SYRE Stock Marks Best Session In About 3 Years — Here’s Why 

Shares of Spyre Therapeutics Inc. (SYRE) closed up 23% on Monday after several analysts upped their price targets on the stock on the heels of positive ulcerative colitis trial data

Equity

Earlier in the day, Spyre said that part of its phase 2 ulcerative colitis trial met its primary endpoint of statistically significant reduction in disease activity.


Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $106.00

Leerink Partners raised their price objective on Spyre Therapeutics from $49.00 to $106.00 and gave the company an "outperform" rating in a research note on Monday...

Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug

Spyre Therapeutics stock jumps after Phase 2 SKYLINE data; SPY001 shows efficacy in ulcerative colitis as analysts maintain bullish outlook.read more...

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

SYRE
Spyre Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SYRE News

SYRESpyre Therapeutics Inc